Crossmark

Ravulizumab as an alternative for gemcitabine related trombotic microangiopathy: A case report

Crossref DOI link: https://doi.org/10.1016/j.nefroe.2025.501356

Published Print: 2025-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Riaza Ortiz, Cristina https://orcid.org/0009-0004-5154-7898
Calvo Arévalo, Marta

Álvarez Nadal, Marta

Casado, Antonio

Sánchez-Fructuoso, Ana I.

García-Carro, Clara
Funding

Funding for this research was provided by:

Alexion Pharmaceuticals
License Information

Text and Data Mining valid from 2025-11-01

Text and Data Mining valid from 2025-11-01

Version of Record valid from 2025-10-19
More Information

This article is maintained by: Elsevier

Article Title: Ravulizumab as an alternative for gemcitabine related trombotic microangiopathy: A case report

Journal Title: Nefrología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nefroe.2025.501356

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.nefro.2025.501356

Content Type: article

Copyright: © 2025 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.